A Randomized, Open-Label, 2x2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg tablet and 2x Lu AA21004 10 mg tablets in Healthy Adult Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Vortioxetine (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Takeda Pharma
- 26 Mar 2018 Planned End Date changed from 9 Sep 2018 to 5 Apr 2018.
- 26 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2018 Status changed from not yet recruiting to recruiting.